Humana (HUM) January 330 puts active as share price down 12%

Go back to Humana (HUM) January 330 puts active as share price down 12%

Piper Sandler Downgrades Humana (HUM) to Neutral

October 3, 2024 9:35 AM EDT

Piper Sandler analyst Jessica Tassan downgraded Humana (NYSE: HUM) from Overweight to Neutral with a price target of $274.00 (from $392.00).

The analyst comments "HUM published an 8K indicating only 1.6M, or 25%, of the company's MA/ SNP members are enrolled in plans rated 4.0+ Stars for 2025.... More

Raymond James Reiterates Market Perform Rating on Humana (HUM)

October 3, 2024 6:17 AM EDT

Raymond James analyst John Ransom reiterated a Market Perform rating and {REMOVEPT} price target on Humana (NYSE: HUM).

The analyst comments "HUM management hosted a call at noon today for the sell side, and the stock had a modest bounce from the initial sell-off, likely due to the not-zero chance that their appeal to CMS might succeed and that there are not zero offsets, including more TBC flexibility and the ability to migrate group MA members to a 4.5 Star plan. At the current price of $247/share (down ~$150 from the recent peak), we... More

Wells Fargo Reiterates Overweight Rating on Humana (HUM)

October 3, 2024 5:55 AM EDT

Wells Fargo analyst Stephen Baxter reiterated an Overweight rating and $387.00 price target on Humana (NYSE: HUM)

The analyst comments "Analysis of Plan Finder. Our review of Medicare Plan Finder suggested that contracts H5216, H5619, H6622, H0028, and H5525 were potentially at risk if filtering functionality was indicative of actual results. Of the... More

Bernstein SocGen Group Reiterates Market Perform Rating on Humana (HUM)

October 3, 2024 5:52 AM EDT

Bernstein SocGen Group analyst Lance Wilkes reiterated a Market Perform rating and $405.00 price target on Humana (NYSE: HUM)

The analyst comments "Yesterday HUM issued a press release outlining their MA offerings for 2025, which was marketing like in tone, presenting how attractive the plans are for... More